CKPT

Checkpoint Therapeutics, Inc. (CKPT) | Rumor.io

Checkpoint Therapeutics

CKPT

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CKPT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.01

Apr 20

Checkpoint Therapeutics (CKPT) was acquired by Sun Pharma in May 2025 for $355M, a 1.18x multiple of its peak sales estimate.
At the time of sale, Checkpoint Therapeutics had zero revenue, suggesting the sale was valued on potential.
The sale price of $355M is equivalent to $13.51 per share, based on the company's peak sales estimate.

Generated by AI

Sentiment

Of the messages about CKPT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	64.71% -19.89
Bearish	—	—	—	35.29% +19.89

Bullish· Mar 10

The short interest in CKPT is almost 21% of the outstanding shares, which could lead to a short squeeze and a significant price increase.
The company has a clear floor price of $4.10 per share, and there's an additional $0.70 contingent on getting the European sales license, which seems likely to be approved soon.
The deal price of $4.10 per share may not be the final price, as another company could offer a higher price, potentially leading to a pump and a significant increase in value.

Bearish· Mar 10

Management's handling of the company has led to the underutilization of a promising drug candidate, resulting in a poor sale price.
The company's acquisition price of $4.10 per share is considered undervalued, with some investors believing the stock is worth at least $20.
The sale of the company's assets has been viewed as a "shameful" and "scam-like" situation, with some investors feeling that long-term shareholders have been left with significant losses.

Generated by AI

Topics

Of the messages about CKPT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	94.44%
Controversies	—	—	—	0%
Earnings	—	—	—	5.56%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Dec 18

The FDA has issued a Complete Response Letter (CRL) for Checkpoint Therapeutics' Biologic License Application (BLA) for cosibelimab due to inspection findings at a third-party manufacturer.
The company believes it can address the FDA's feedback in a resubmission, potentially enabling marketing approval for cosibelimab in 2024.
The FDA supports the efficacy of cosibelimab but is urging fine-tuning of the manufacturing process to secure approval.

Generated by AI

Community

Of the messages about CKPT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	17.65%
Newcomers	—	—	—	82.35%

Regulars· Dec 16

The regulars are discussing the ban of CKPT on the r/wallstreetbets community due to its low market cap.
The ban is aimed at preventing pump and dump spam and scammers from manipulating the stock price.
The community's low market cap threshold for ban is 500 million, which is currently below CKPT's market value.

Newcomers· Dec 20

The newcomer is optimistic about Checkpoint Therapeutics, Inc. ($CKPT) and thinks it has a strong catalyst for growth.
One newcomer believes $CKPT is close to a significant price increase, citing an 11% rise.
The newcomer is aware of $CKPT's warrants and thinks they could be a valuable opportunity.

Generated by AI

Also Discussed

Investors talking about CKPT also mention

#	Name	Attention
1	Fortress Biotech, Inc.FBIO	0%0
2	TG Therapeutics Inc.TGTX	0.01%+0
3	Mustang Bio Inc.MBIO	0%0
4	Journey Medical Corp. Common StockDERM	0%0
5	Coherus Oncology, Inc.CHRS	0%0
6	Avenue Therapeutics Inc.ATXI	0%new
7	X4 Pharmaceuticals, Inc.XFOR	0%0
8	OPTN - OptiNose, Inc.	——
9	Karyopharm Therapeutics Inc.KPTI	0%new
10	Autolus Therapeutics plc ADRAUTL	0%+0